ReviewDrug safety2019

Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

Anthony Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.